 |
 |
| 5-Year Data |
|
|
See the results of the longest reported controlled clinical study of male pattern hair loss. |
|
|
| View study results. |
|
 |
 |
|
|
|
|
| Photographic Assessment |
|
 |
|
| In the longest reported controlled clinical study of male pattern hair loss patients ever conducted ... |
| The majority of men treated with PROPECIA® (finasteride) showed improvement or no visible hair loss1 |
|
Global photographic assessment of the vertex by an expert panel of dermatologists showed: |
|
 |
90% of the men treated with PROPECIA at 5 years had improvement or no visible hair loss (48% of patients improved, 42% had no visible hair loss) vs 25% of men in the placebo group (6% improved, 19% had no visible hair loss). |
|
|
 |
|
|
|
BASELINE
YEAR 5 |
|
 |
|
 |
|
 |
|
 |
|
|
 |
|
 |
|
|
|
 |
|
 |
|
 |
|
 |
|
|
 |
|
 |
|
|
|
|
GREAT IMPROVEMENT
5% |
|
MODERATE IMPROVEMENT
21% |
|
SLIGHT IMPROVEMENT
22% |
|
NO VISIBLE HAIR LOSS
42% |
|
|
SLIGHT DECREASE
7% |
|
MODERATE DECREASE
3% |
|
|
|
|
|
PROPECIA is the first oral therapy indicated for the treatment of male pattern hair loss in MEN ONLY. Safety and efficacy were demonstrated in men, aged 18 to 41, with mild to moderate hair loss of the vertex and anterior mid-scalp area. Efficacy in bitemporal recession has not been established. |
| |
|
PROPECIA is not indicated in women or children. |
| |
|
|
|
In clinical studies of 1 year for PROPECIA, each drug-related sexual adverse event occurred in less than 2% of men. Discontinuation due to drug-related sexual adverse experiences was 1.2% in the group treated with PROPECIA and 0.9% in the placebo-treated group. Reported drug-related sexual adverse experiences included decreased libido (1.8% vs 1.3%, placebo), erectile dysfunction (1.3% vs 0.7%, placebo), and ejaculation disorders (1.2% vs 0.7%, placebo), primarily decreased volume of ejaculate (0.8% vs 0.4%, placebo). |
|
|
|
